STAT Plus Tyme Technologies misleads with new data on pancreatic cancer drug
STAT Plus: Tyme Technologies misleads with new data on pancreatic cancer drug
08:25 EST 18 Jan 2019 |
STAT
Why a company's interpretation of a study about pancreatic cancer should be seen with skepticism.
More From BioPortfolio on "STAT Plus: Tyme Technologies misleads with new data on pancreatic cancer drug"